The Structure of Biological Therapeutics

Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals

Volumn , Issue , 2010, Pages 1-40

  Martin Moe, Sheryl ^a   Osslund, Tim ^b   Wang, Y John ^a   Mahmood, Tahir ^c   Deshpande, Rohini ^b   Hershenson, Susan ^a  

^a GENENTECH INC   (United States)

^b AMGEN INC   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Antibodies or immunoglobulin proteins in response to non self antigens, defence against pathogenic organisms and toxins; Stability indicating assays, preformulation and biophysical characterization structure of biological therapeutics; Therapeutic protein alternatives to antibody derived scaffolds

Indexed keywords

EID: 79955790949     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470595886.ch1     Document Type: Chapter

References (133)

1. Hoffmann, F., (1900), U.S. Patent #644,677, "Acetylsalicylic acid" assigned to Farben- Fabriken of Elberfeld Co., New York.
2. Bliss, M. (1982), The Discovery of Insulin, Univ. Chicago Press.
3. Frasier, S. D. (1997), The not-so-good old days: Working with pituitary growth hormone in North America, 1956 to 1985, J. Pediatr. 131: S1-S4.
4. Brown, P. et al. (2000), Iatrogenic Creutzfeldt-Jakob disease at the millennium, Neurology 55: 1075-1081.
5. Cohn, E. J. (1945), Blood proteins and their therapeutic value, Science 101: 51-56.
6. Berger, M. (1999), A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies, Curr. Allergy Asthma Rep. 2: 368-378.
7. Resnik, S. (1999), Blood Saga: Hemophilia, AIDS, and the Survival of a Community, Univ. California Press, Berkeley.
8. James, R. (1968), Wall Street J. Hope for 'Bleeders', page 1.
9. Enck, R. E., Betts, R. F., Brown, M. R., and Miller, G. (1979), Viral serology (hepatitis B virus, cytomegalovirus, Epstein-Barr virus) and abnormal liver function tests in transfused patients with hereditary hemorrhagic diseases, Transfusion 19: 32-38.
10. Curran, J. W. et al. (1984), Acquired immunodeficiency syndrome (AIDS) associated with transfusions, New Engl. J. Med. 310: 69-75.
11. Bray, B. L. (2003), Large-scale manufacture of peptide therapeutics by chemical synthesis, Nat. Rev. 2: 587-593.
12. Cohen, S. N., Chang, A. C. Y., Boyer, H. W., and Helling, R. B. (1973), Construction of biologically functional bacterial plasmids in vitro, Proc. Natl. Acad. Sci. USA 70: 3240-3244.
13. Verma, R., Boleti, E., and George, A. J. (1998), Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems, J Immunol. Meth. 216: 165-181.
14. Leader, B., Baca, Q. J., and Golan, D. E. (2008), Protein therapeutics: A summary and pharmacological classification, Nat. Rev. 7: 21-39.
15. Kohler, G. and Milstein, C. (1975), Continuous cultures of fused cells secreting antibody of predefined specificity, Nature 256: 495-497.
16. FDA Website (2009), Licensed product approvals for biological drugs. URL: www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
17. Jakobovits, A., Amado, R. G., Yang, X., Roskos, L., and Schwab, G. (2007), From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice, Nat. Biotechnol. 25: 1134-1143.
18. Reichert, J. M. and Valge-Archer, V. E. (2007), Development trends for monoclonal antibody cancer therapeutics, Nat. Rev. 6: 349-356.
19. Carter, P. J. (2006), Potent antibody therapeutics by design, Nat. Rev. Immunol. 6: 343-357.
20. Baker, M. (2005), Upping the ante on antibodies, Nat. Biotechnol. 23: 1065-1072.
21. Itakura, K. et al. (1977), Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin, Science 198: 1056-1063.
22. Goeddel, D. V. et al. (1979), Expression in Escherichia coli of chemically synthesized genes for human insulin, Proc. Natl. Acad. Sci. USA 76: 106-110.
23. Goeddel, D. V. et al. (1979), Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone, Nature 281: 544-548.
24. Walsh, G. (2003), Biopharmaceuticals: Biochemistry and Biotechnology, 2nd ed., Wiley, Hoboken, NJ.
25. Brange, J. and Langkjær, L. (1993), Insulin Structure and Stability in Stability and Characterization of Protein and Peptides Drugs, Y. John Wang and Rodney Pearlman ed., Springer Dordrecht p. 315.
26. Brange, J. and Volund, A. (1999), Insulin analogs with improved pharmacokinetic profiles, Adv. Drug Deliv. Rev. 35: 307-335.
27. Mersebach, H. F. S., Sparre, T., and Jensen, L. B. (2008), in Immunogenecity of Biopharmaceuticals, van de Weert, M. and Moller, E. ed., Springer.
28. Frank, B., Pettee, J., Zimmerman, R., and Burck, P. (1981), Peptides: Synthesis-Structure- Function, Pierce Chemical Co.
29. Brange, J. et al. (1988), Monomeric insulins obtained by protein engineering and their medical implications, Nature 333: 679-682.
30. Olsen, H. B. and Kaarsholm, N. C. (2000), Structural effects of protein lipidation as revealed by LysB29-myristoyl, des(B30) insulin, Biochemistry 39: 11893-11900.
31. Yuan, L., Wang, J., and Shen, W. C. (2005), Reversible lipidization prolongs the pharmacological effect, plasma duration, and liver retention of octreotide, Pharm. Res. 22: 220-227.
32. Moore, W. V. and Leppert, P. (1980), Role of aggregated human growth hormone (hGH) in development of antibodies to hGH, J. Clin. Endocrinol. Metab. 51: 691-697.
33. Brown, P., Gajdusek, D. C., Gibbs, C. J., Jr., Asher, D. M. (1985), Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy, New Engl. J. Med. 313: 728-731.
34. Haan, C., Kreis, S., Margue, C., and Behrmann, I. (2006), Jaks and cytokine receptors-an intimate relationship, Biochem. Pharmacol. 72: 1538-1546.
35. Hill, C. P., Osslund, T. D., and Eisenberg, D. (1993), The structure of granulocyte-colonystimulating factor and its relationship to other growth factors, Proc. Nat. Acad. Sci. 90: 5167-5171.
36. Brandhuber, B. J., Boone, T., Kenney, W. C., and McKay, D. B. (1987), Three-dimensional structure of interleukin-2, Science 238: 1707-1709.
37. Bazan, J. F. (1992), Unraveling the structure of IL-2, Science 257: 410-413.
38. Geigert, J. and Ghrist, F. D. (1996), Development and shelf-life determination of recombinant human granulocyte-macrophage colony-stimulating factor (LEUKINE, GM-CSF), Pharm. Biotechnol. 9: 329-342.
39. Kinstler, O., Molineux, G., Treuheit, M., Ladd, D., and Gegg, C. (2002), Mono-N-terminal poly(ethylene glycol)-protein conjugates, Adv. Drug Deliv. Rev. 54: 477-485.
40. Kinstler, O. B. et al. (1996), Characterization and stability of N-terminally PEGylated rhG-CSF, Pharm. Res. 13: 996-1002.
41. Elliott, S. et al. (2003), Enhancement of therapeutic protein in vivo activities through glycoengineering, Nat. Biotechnol. 21: 414.
42. Macdougall, I. C. (2008), Novel erythropoiesis-stimulating agents: A new era in anemia management, Clin. J. Am. Soc. Nephrol. 3: 200-207.
43. Seto, M. H. et al. (1995), Homology model of human interferon-{alpha}8 and its receptor complex, Protein Sci. 4: 655-670.
44. Wang, Y. S. et al. (2002), Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications, Adv. Drug Deliv. Rev. 54: 547-570.
45. Rajender, R., Modi, M. W., and Pedder, S. (2002), Use of peginterferon alfa-2a (40KD) (Pegasys) for the treatment of hepatitis C, Adv. Drug Deliv. Rev. 54: 571-586.
46. Karpusas, M. et al. (1997), The crystal structure of human interferon beta at 2.2-A resolution, Proc. Natl. Acad. Sci. 94: 11813-11818.
47. Ealick, S. E. et al. (1991), Three-dimensional structure of recombinant human interferongamma, Science 252: 698-702.
48. Jiang, X. et al. (2000), Structure of the active core of human stem cell factor and analysis of binding to its receptor kit, Embo. J. 19: 3192-3203.
49. Osslund, T. D. et al. (1998), Correlation between the 1.6 A crystal structure and mutational analysis of keratinocyte growth factor, Protein Sci. 7: 1681-1690.
50. NIH (2009), Clinical Trials Monitored by the National Institutes of Health (NIH ). URL: http://clinicaltrials.gov
51. Schreuder, H. et al. (1997), A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist, Nature 386: 194-200.
52. McDonald, N. Q. et al. (1991), New protein fold revealed by a 2.3-A resolution crystal structure of nerve growth factor, Nature 354: 411-414.
53. Murray-Rust J. M. N., Blundell, T. L., Hosang, M., Oefner, C., Winkler, F., and Bradshaw, R. A. (1993), Topological similarities in TGF-beta 2, PDGF-BB and NGF define a superfamily of polypeptide growth factors, Structure 1(2): 153-159.
54. FDA (2009), Website for device approvals. Center for Devices and Radiological Health URL: www.fda.gov/cdrh/mda
55. Walsh, G. (1998), Biopharmaceuticals: Biochemistry and Biotechnology, Wiley, New York.
56. Fay, P. J. (1993), Factor VIII structure and function, Thromb. Haemost. 70: 63-67.
57. Vehar, G. A. et al. (1984), Structure of human factor VIII, Nature 312: 337-342.
58. Pittman, D. D., Wang, J. H., and Kaufman, R. J. (1992), Identification and functional importance of tyrosine sulfate residues within recombinant factor VIII, Biochemistry 31: 3315-3325.
59. McMullen, B. A., Fujikawa, K., Davie, E. W., Hedner, U., and Ezban, M. (1995), Locations of disulfide bonds and free cysteines in the heavy and light chains of recombinant human factor VIII (antihemophilic factor A), Protein Sci. 4: 740-746.
60. Mikaelsson, M. E., Forsman, N., and Oswaldsson, U. M. (1983), Human factor VIII: A calcium-linked protein complex, Blood 62: 1006-1015.
61. Bennett, W. F. et al. (1991), High resolution analysis of functional determinants on human tissue- type plasminogen activator, J. Biol. Chem. 266: 5191-5201.
62. de Vos, A. M., Ultsch, M. H., Kelley, R. F., Padmanabhan, K., Tulinsky, A., Westbrook, M. L., and Kossiakoff, A. A. (1992), Crystal structure of the kringle 2 domain of tissue plasminogen activator at 2.4-A, Biochemistry 31: 270-279.
63. Nguyen, T. H. and Ward, C. (1993), Stability characterization and formulation development of alteplase, a recombinant tissue plasminogen activator, Pharm. Biotechnol. 5: 91-134.
64. Mattes, R. (2001), The production of improved tissue-type plasminogen activator in Escherichia coli, Semin. Thromb. Hemost. 27: 325-336.
65. Shire, S. J. (1996), Stability characterization and formulation development of recombinant human deoxyribonuclease I [Pulmozyme (dornase alpha)], Pharm. Biotechnol. 9: 393-426.
66. Edmunds, T. (1998), Cerezyme: A case study, Devel. Biol. Stand. 96: 131-140.
67. AuBuchon, J. P., Birkmeyer, J. D., and Busch, M. P. (1997), Safety of the blood supply in the United States: Opportunities and controversies, Ann. Intern. Med. 127: 904-909.
68. Kolls, J., Peppel, K., Silva, M., and Beutler, B. (1994), Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer, Proc. Natl. Acad. Sci. USA 91: 215-219.
69. Bussel, J. B. et al. (2006), AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP, New Engl. J. Med. 355: 1672-1681.
70. Mascelli, M. A. et al. (2007), Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: Impact of these parameters on early clinical development, J. Clin. Pharmacol. 47: 553-565.
71. Presta, L. G. (2005), Selection, design, and engineering of therapeutic antibodies, J. Allergy Clin. Immunol. 116: 731-736; quiz 737.
72. Harris, L., Skaletsky, E., and McPhorsen, A., (1998), Crystallographic structure of an intact IgG1 monoclonal antibody. J. Mol. Biol. 275: 8610.
73. Honegger, A., et al. (2005), A mutation designed to alter crystal packing permits structural analysis of a tight-binding fluorescein-scFv complex. Protein Sci. 14: 2537.
74. Carmichael, J., et al. (2003), The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility. J. Mol. Biol. 326: 341.
75. Ewert, S., Huber, T., Honegger, A., and Pluckthun, A. (2003), Biophysical properties of human antibody variable domains, J. Mol. Biol. 325: 531-553.
76. Stanfield, R. L., Zemla, A., Wilson, I. A., and Rupp, B. (2006), Antibody elbow angles are influenced by their light chain class, J. Mol. Biol. 357: 1566-1574.
77. Caruthers, M. H. (1985), Gene synthesis machines: DNA chemistry and its uses, Science 230: 281-285.
78. Roux, K. H., Strelets, L., Brekke, O. H., Sandlie, I., and Michaelsen, T. E. (1998), Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: A role for flexibility and geometry, J. Immunol. 161: 4083-4090.
79. Brekke, O. H., Michaelsen, T. E., and Sandlie, I. (1995), The structural requirements for complement activation by IgG: does it hinge on the hinge?. Immunol. Today 16: 85-90.
80. Wang, W., Singh, S., Zeng, D. L., King, K., and Nema, S. (2007), Antibody structure, instability, and formulation, J. Pharm. Sci. 96: 1-26.
81. Salfeld, J. G. (2007), Isotype selection in antibody engineering, Nat. Biotechnol. 25: 1369-1372.
82. Aalberse, R. C. and Schuurman, J. (2002), IgG4 breaking the rules, Immunology 105: 9-19.
83. Lu, Y. et al. (2008), The effect of a point mutation on the stability of IgG4 as monitored by analytical ultracentrifugation, J. Pharm. Sci. 97: 960-969.
84. Weiner, L. M. and Carter, P. (2005), Tunable antibodies, Nat. Biotechnol. 23: 556-557.
85. Anand, B. (2008), in Pharmaceutical Biotechnology, 3rd ed., Crommelin R. S. D. and Meibohm, B., eds., Informa Healthcare, New York, p. 466.
86. Cohen-Solal, J. F., Cassard, L., Fridman, W. H., and Sautes-Fridman, C. (2004), Fc gamma receptors, Immunol. Lett. 92: 199-205.
87. Sondermann, P., Kaiser, J., and Jacob, U. (2001), Molecular basis for immune complex recognition: A comparison of Fc-receptor structures, J. Mol. Biol. 309: 737-749.
88. Lazar, G. A. et al. (2006), Engineered antibody Fc variants with enhanced effector function, Proc. Natl. Acad. Sci. USA 103: 4005-4010.
89. Shields, R. L. et al. (2001). High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R, J. Biol. Chem. 276: 6591-6604.
90. Roskos, L., Davis, C. G., and Schwab, G. M. (2004), The clinical pharmacology of therapeutic monoclonal antibodies, Drug Devel. Res. 61: 108-120.
91. Amgen press release (2009), Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women with Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation for Either Prostate or Breast Cancer.
92. McClung, M. R. et al. (2006), Denosumab in postmenopausal women with low bone mineral density, New Engl. J. Med. 354: 821-831.
93. Cohen, S. B. et al. (2008), Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial, Arthritis Rheum. 58: 1299-1309.
94. Reichert, J. M. and Wenger, J. B. (2008), Development trends for new cancer therapeutics and vaccines, Drug Discov. Today 13: 30-37.
95. Lonberg, N. (2005), Human antibodies from transgenic animals, Nat. Biotechnol. 23: 1117-1125.
96. Presta, L. G. (2006), Engineering of therapeutic antibodies to minimize immunogenicity and optimize function, Adv. Drug Deliv. Rev. 58: 640-656.
97. Moolten, F. L. and Cooperband, S. R. (1970), Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells, Science 169: 68-70.
98. Hurwitz, E., Levy, R., and Maron, R. (1975), Proceedings: Daunomycin and adriamycin antitumor cell antibody conjugates, Isr. J. Med. Sci. 11: 1396.
99. Schrama, D., Reisfeld, R. A., and Becker, J. C. (2006), Antibody targeted drugs as cancer therapeutics, Nat. Rev. 5: 147-159.
100. Wu, A. M. and Senter, P. D. (2005), Arming antibodies: Prospects and challenges for immunoconjugates, Nat. Biotechnol. 23: 1137-1146.
101. Hulett, M. D. and Hogarth, P. M. (1994), Molecular basis of Fc receptor function, Adv. Immunol. 57: 1-127.
102. Hinman, L. M. et al. (1993), Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics, Cancer Res. 53: 3336-3342.
103. Carter, P. J. and Senter, P. D. (2008), Antibody-drug conjugates for cancer therapy, Cancer J. 14: 154-169.
104. Ferrara, N., Damico, L., Shams, N., Lowman, H., and Kim, R. (2006), Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration, Retina 26: 859-870.
105. Chen, Y. et al. (1999), Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen, J. Mol. Biol. 293: 865-881.
106. Gaudreault, J., Fei, D., Rusit, J., Suboc, P., and Shiu, V. (2005), Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration, Invest Ophthalmol. Vis. Sci. 46: 726-733.
107. Chapman, A. P. et al. (1999), Therapeutic antibody fragments with prolonged in vivo half-lives, Nat. Biotechnol. 17: 780-783.
108. Holliger, P. and Hudson, P. J. (2005), Engineered antibody fragments and the rise of single domains, Nat. Biotechnol. 23: 1126-1136.
109. Muyldermans, S. (2001), Single domain camel antibodies: Current status, J. Biotechnol. 74: 277-302.
110. Linsley, P. S. (2005), New look at an old costimulator, Nat. Immunol. 6: 231-232.
111. Teeling, J. L. et al. (2004), Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas, Blood 104: 1793-1800.
112. Holliger, P. et al. (1999), Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins, Cancer Res. 59: 2909-2916.
113. Kipriyanov, S. M. et al. (1996), Affinity enhancement of a recombinant antibody: Formation of complexes with multiple valency by a single-chain Fv fragment-core streptavidin fusion, Protein Eng. 9: 203-211.
114. Oh, P. et al. (2004), Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy, Nature 429: 629-635.
115. Halin, C. et al. (2002), Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature, Nat. Biotechnol. 20: 264-269.
116. Yang, A. S. and Honig, B. (2000), An integrated approach to the analysis and modeling of protein sequences and structures. III. A comparative study of sequence conservation in protein structural families using multiple structural alignments, J. Mol. Biol. 301: 691-711.
117. Olson, C. A. and Roberts, R. W. (2007), Design, expression, and stability of a diverse protein library based on the human fibronectin type III domain, Protein Sci. 16: 476-484.
118. Koide, A., Bailey, C. W., Huang, X., and Koide, S. (1998), The fibronectin type III domain as a scaffold for novel binding proteins, J. Mol. Biol. 284: 1141-1151.
119. Lander, E. S. et al. (2001), Initial sequencing and analysis of the human genome, Nature 409: 860-921.
120. Forrer, P., Binz, H. K., Stumpp, M. T., and Pluckthun, A. (2004), Consensus design of repeat proteins, Chembiochem 5: 183-189.
121. Kohl, A. et al. (2003), Designed to be stable: Crystal structure of a consensus ankyrin repeat protein, Proc. Natl. Acad. Sci. USA 100: 1700-1705.
122. Zahnd, C. et al. (2007), A designed ankyrin repeat protein evolved to picomolar affinity to Her2, J. Mol. Biol. 369: 1015-1028.
123. Weiss, G. A. and Lowman, H. B. (2000), Anticalins versus antibodies: made-to-order binding proteins for small molecules, Chem. Biol. 7: R177-R184.
124. Skerra, A. (2000), Lipocalins as a scaffold, Biochim. Biophys. Acta 1482: 337-350.
125. Beste, G., Schmidt, F. S., Stibora, T., and Skerra, A. (1999), Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold, Proc. Natl. Acad. Sci. USA 96: 1898-1903.
126. Ebersbach, H. et al. (2007), Affilin-novel binding molecules based on human gamma-Bcrystallin, an all beta-sheet protein, J. Mol. Biol. 372: 172-185.
127. Werle, M. et al. (2006), The potential of cystine-knot microproteins as novel pharmacophoric scaffolds in oral peptide drug delivery, J. Drug Target 14: 137-146.
128. Werle, M., Kafedjiiski, K., Kolmar, H., and Bernkop-Schnurch, A. (2007), Evaluation and improvement of the properties of the novel cystine-knot microprotein McoEeTI for oral administration, Int. J. Pharm. 332: 72-79.
129. Silverman, J. et al. (2005), Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains, Nat. Biotechnol. 23: 1556-1561.
130. Thogersen, C. and Holldack, J. (2006), A tetranectin-based platform for protein engineering, Innov. Pharm. Technol. 27-30.
131. Watt, P. M. (2006), Screening for peptide drugs from the natural repertoire of biodiverse protein folds, Nat. Biotechnol. 24: 177-183.
132. Shire, S. J., Shahrokh, Z., and Liu, J. (2004), Challenges in the development of high protein concentration formulations, J. Pharm. Sci. 93: 1390-1402.
133. Lobo, E. D., Hansen, R. J., and Balthasar, J. P. (2004), Antibody pharmacokinetics and pharmacodynamics, J. Pharm. Sci. 93: 2645-2668.